Association of cardiovascular emerging risk factors with acute coronary syndrome and stroke: A case-control study

"This is the pre-peer reviewed version of the following article: "Martínez Linares, J.M.; et al. Association of cardiovascular emerging risk factors with acute coronary syndrome and stroke: A case control study. Nursing and Health Sciences, 18(4): 488-495 (2016)", which has been published in final form at http://dx.doi.org/10.1111/nhs.12299 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving."In this study, we estimated the risk of acute coronary syndrome and stroke associated with several emerging cardiovascular risk factors. This was a case-control study, where an age - and sex-matched acute coronary syndrome group and stroke group were compared with controls. Demographic and clinical data were collected through patient interviews, and blood samples were taken for analysis. In the bivariate analysis, all cardiovascular risk factors analyzed showed as predictors of acute coronary syndrome and stroke, except total cholesterol and smoking. In the multivariate logistic regression model for acute coronary syndrome, hypertension and body mass index, N-terminal section brain natriuretic peptide and pregnancy-associated plasma protein-Awere independent predictors. For stroke, the predictors were hypertension, diabetes mellitus, body mass index, and N-terminal section brain natriuretic peptide. Controlling for age, sex, and classical cardiovascular risk factors, N-terminal section brain natriuretic peptide and pregnancy-associated plasma protein-A were independent emerging cardiovascular risk factors for acute coronary syndrome, but pregnancy-associated plasma protein-A was not for stroke. High levels of cardiovascular risk factors in individuals with no episodes of cardiovascular disease requires the implementation of prevention programs, given that at least half of them are modifiable.Health Agency of Health South of Granada.Project from "Ministerio de Economía y Competitividad. Dirección General de Investigación Científica y Técnica". Grant Number: MTM2013-47929-

Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial

Background: An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins.Objective: To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159).Methods and Findings: Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B₆ and B₁₂ in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B₁₂ (0.5 mg/d) and vitamin B₆ (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans.Results: A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P=0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine &gt; 13μmol/L was 53% lower in the active treatment group (P=0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category.Conclusions and significance: The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease.</p

Is late-onset Alzheimer's disease really a disease of midlife?

AbstractIntroductionIncreasing evidence suggests that Alzheimer's disease (AD) may begin decades before evidence of dementia, indicating that it may be a disorder of midlife rather than old age.MethodsIn the absence of long-term prospective studies from early adulthood specifically designed to address this question, a group of international experts examined evidence presently available from previous clinical and population studies to provide an evidence-based opinion as to whether such a change in conceptualization may be justified.ResultsAlthough still lacking confirmation from dedicated prospective biomarker studies, there is already considerable evidence to suggest both risk factor exposure and brain changes may be already present in midlife.DiscussionCurrent evidence suggests (1) that a change in clinical approach notably involving promotion of cardiovascular health in persons with a family history of AD may considerably reduce disease risk and (2) that the development of biomarkers at this early stage will lead to the possibility of clinical trials at a much earlier stage

Inquiétant arrêt de la Cour de justice dans l'affaire Meca-Medina. Ou comment 2 nanogrammes de nandrolone pourraient bouleverser le sport européen

Jurisprudence : Cour de justice des Communautés européennes, 18 juillet 2006, aff. C-519/04P. Réglementation antidopage et règles communautaires de la concurrence : l'affaire portait sur la compatibilité de règles édictées par une fédération sportive avec le droit communautair

L'arrêt Olivier Bernard : une avancée significative pour la formation des joueurs

Note sous CJUE, grande chambre, 16 mars 2010, aff. C-325/08 (Olympique Lyonnais SASP c/ Olivier Bernard, Newcastle UFC). La Cour à reconnu la légitimité des indemnités de formation en même temps qu'elle a fixé les limites à l'intérieur desquelles celles-ci peuvent être calculées. Cette décision affermit encore davantage les efforts déployés par les fédérations sportives pour protéger et encourager la formation des jeunes sportifs (professionnels)